Liver fibrosis, insulin resistance and cardiovascular risk scores in obese and non-obese patients with non-alcoholic fatty liver disease
Novelty in Biomedicine,
Vol. 13 No. 2 (2025),
19 April 2025
,
Page 81-86
https://doi.org/10.22037/nbm.v13i2.46649
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Obese children and adolescents, particularly those with metabolic syndrome (MetS), commonly report NAFLD, which can lead to various other problems and diseases. There are different opinions on how the liver fibrosis score, insulin resistance indices, and risk of cardiovascular disease are related in people with NAFLD who have different body mass index (BMI) levels. This study aimed to investigate the relationship between liver fibrosis score, insulin resistance indices, and cardiovascular disease risk in patients with NAFLD, specifically focusing on two groups with normal and high BMI.
Materials and Methods: This analytical cross-sectional study was conducted on patients with NAFLD referred to Taleghani Hospital (Tehran-Iran) between 2019 and 2020. Data such as age, gender, BMI, height, weight, blood sugar level, hemoglobin A1C level, lipid profile, liver fibrosis level, insulin resistance level, liver aminotransferases level, Framingham risk score, and presence of MetS were evaluated. The significance level was considered less than 0.05.
Results: We evaluated 140 patients, 14 of whom had normal BMI, and the rest had high BMI. There was a significant relationship between the homeostatic model assessment for insulin resistance (HOMA-IR) index and the liver fibrosis score. For a one-unit increase in the liver fibrosis score, the HOMA-IR score increased by 0.287 times (P-value=0.001). There was a significant relationship between MetS and the risk of cardiovascular diseases based on the Framingham risk score and liver fibrosis (P-values<0.05).
Conclusion: High BMI levels can increase the incidence of NAFLD, Framingham, and HOMA-IR indices.
- Liver fibrosis score
- Insulin resistance index
- Non-alcoholic fatty liver
- Obesity
- Body mass index
How to Cite
References
Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. Journal of pediatric gastroenterology and nutrition. 2012;54(5):700-13.
Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of pediatric gastroenterology and nutrition. 2017;64(2):319.
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC medicine. 2017;15(1):1-6.
Kumar S, Kelly AS, editors. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clinic Proceedings; 2017: Elsevier.
Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul medical. 2018;91(2):147.
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. New England journal of medicine. 2004;350(23):2362-74.
Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology. 2008;49(4):600-7.
Burrage E, Marshall KL, Santanam N, Chantler PD. Cerebrovascular dysfunction with stress and depression. Brain circulation. 2018;4(2):43-53.
Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. The American journal of cardiology. 2004;94(1):20-4.
Nogueira JP, Cusi K. Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care. Diabetes Spectrum. 2024;37(1):20-8.
Burrage E, Marshall KL, Santanam N, Chantler PD. Cerebrovascular dysfunction with stress and depression. Brain circulation. 2018;4(2):43.
van der Pal KC, Koopman AD, Lakerveld J, van der Heijden AA, Elders PJ, Beulens JW, et al. The association between multiple sleep-related characteristics and the metabolic syndrome in the general population: the New Hoorn study. Sleep Medicine. 2018;52:51-7.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
Diniz MdFHS, Beleigoli AMR, Schmidt MI, Duncan BB, Ribeiro ALP, Vidigal PG, et al. Homeostasis model assessment of insulin resistance (HOMA-IR) and metabolic syndrome at baseline of a multicentric Brazilian cohort: ELSA-Brasil study. Cadernos de saude publica. 2020;36:e00072120.
Weir C, Jan A. BMI classification percentile and cut off points.[Updated 2021 Jun 29]. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; Available from https://www ncbi nlm nih gov/books/NBK541070. 2022.
Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. Journal of Clinical Medicine. 2018;7(12):562.
Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in non-obese Indian patients with non-alcoholic fatty liver. Tropical Gastroenterology. 2013;34(1):18-24.
Djalalinia S, Saeedi Moghaddam S, Sheidaei A, Rezaei N, Naghibi Iravani SS, Modirian M, et al. Patterns of obesity and overweight in the iranian population: findings of steps 2016. Frontiers in endocrinology. 2020;11:42.
Abdi F, Atarodi Z, Mirmiran P, Esteki T. Review of nutritional status in Iranian population. Focus Sci. 2016;2(3):1-10.
Valle-Martos R, Valle M, Martos R, Cañete R, Jiménez-Reina L, Cañete MD. Liver enzymes correlate with metabolic syndrome, inflammation, and endothelial dysfunction in prepubertal children with obesity. Frontiers in Pediatrics. 2021;9:629346.
Gentili A, Daviddi G, De Vuono S, Ricci MA, Di Filippo F, Alaeddin A, et al. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Digestive and Liver Disease. 2016;48(8):904-8.
Lee S-R, Han K-D, Choi E-K, Oh S, Lip GY. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Scientific reports. 2021;11(1):1-9.
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & metabolic syndrome. 2020;12(1):1-20.
Chen Y-l, Li H, Li S, Xu Z, Tian S, Wu J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC gastroenterology. 2021;21(1):1-12.
Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, et al. Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. European journal of endocrinology. 2019;181(2):185-92.
- Abstract Viewed: 152 times
- pdf Downloaded: 123 times